Compositions, methods and systems for the treatment of a protein aggregation disease including, but not limited to Alzheimer's disease (AD), Parkinson's disease (PD), Dementia with Lewy Bodies (DLB), Huntington's disease (HD), Amylotrophic lateral sclerosis (ALS, which results from degeneration of the upper and lower motor neurones and affects the voluntary muscle system), Progressive Supranuclear Palsy (PSP), Type 2 Diabetes and Multiple systems atrophy (MSA).

A blood purification device includes a chamber, a liquid feed line, an air introduction unit, a liquid level adjustment unit, and a control unit. The chamber is provided on a blood circuit for extracorporeally circulating patient's blood and introduces purified plasma obtained by purifying plasma separated by a plasma separator provided on the blood circuit, or a replenishing liquid for replenishing the plasma separated by the plasma separator, into the blood circuit. The liquid feed line is capable of sending the purified plasma or the replenishing liquid to the chamber. The air introduction unit is capable of introducing air into the liquid feed line. The liquid level adjustment unit is capable of adjusting a liquid level height in the chamber. At the end of blood purification treatment, the control unit performs a liquid recovery process for sending the purified plasma or the replenishing liquid to the chamber via the liquid feed line while introducing air into the liquid feed line by the air introduction unit and maintains the liquid level height in the chamber at a predetermined liquid level height by the liquid level adjustment unit.

Provided is a blood purifier which has a porous molded body with good phosphorus adsorption, which has good cytokine adsorption performance, no hemolysis, and can be used safely. The blood purifier has a porous molded body having a low-melting-point moisture content per gram of dry weight of 0.12 g or more and 1.35 g or less. After three and six months from sealing of a saline solution for injection into the blood purifier, the number of microparticles greater than or equal to 10 μm is 25 or less and the number of microparticles greater than or equal to 25 μm is three or less in 1 mL of the saline solution for injection.

A sorbent cartridge for use in a portable wearable renal therapy system, and a method of using same is provided. The sorbent cartridge comprises: a inlet and an outlet, the inlet configured to receive process fluid from renal therapy device and the outlet configured to discharge treated process fluid; a hydrogel configured to absorb and adsorb a toxin from the process fluid without use of a dialysate to purify the process fluid. The inlet and the outlet are each configured to releasably couple to the renal therapy device for removing the sorbent cartridge.

The present invention aims to provide a material for adsorbing soluble tumor necrosis factor receptors with high efficiency. The present invention provides an adsorbing material for soluble tumor necrosis factor receptors, which includes a superficially porous water-insoluble polymeric material, wherein the pore size distribution curve for the surface of the water-insoluble polymeric material, which is derived from a distribution of melting points determined by differential scanning calorimeter, shows the peak radius in the range of 1 to 80 nm, and the water-insoluble polymeric material has a zeta potential at pH 7.4 of −15 to 15 mV, and the water-insoluble polymeric material is in fiber, particle, or film form.

The present invention provides biological molecules for use in detecting, identifying and/or removing microbes and microbial components; diagnostic, therapeutic and filtration devices comprising the biological molecules; and systems and methods for treating fluids using the biological molecules and devices of the invention.

A whole blood treatment device includes a cartridge configured to receive whole blood, having a wall defining an interior volume, an inlet, and an outlet, a support structure having a surface, inside of the cartridge, and an affinity agent, attached to the surface of the support structure. The affinity agent is effective to bind to a target agent that is desirable for removal from a patient. The target agent is selected from the group consisting of: inhibitory checkpoint molecules, inflammatory factors, cancerous cells, autoantibodies, opioids and heavy metals. A method of removing a target agent from whole blood of a patient in a whole blood treatment device comprising pumping whole blood into a cartridge, containing a support structure having a surface, with a plurality of affinity agents on the support structure, to contact the whole blood with the affinity agents; binding the target agent with the affinity agents; and removing the whole blood having a reduced amount of the target agent from the cartridge. The target agent is selected from the group consisting of: inhibitory checkpoint molecules, inflammatory factors, cancerous cells, autoantibodies, opioids and heavy metals.

An embodiment provides a method for treating a body fluid of a patient with Covid-19, including: removing the body fluid from a patient, wherein the body fluid comprises a Covid-19 targeted pathogenic antigen (TPA); applying a treatment to the body fluid, wherein the treatment comprises an antibody that joins with the Covid-19 targeted pathogenic antigen in the body fluid to form an antibody-TPA complex, wherein the antibody comprises a radiofrequency absorption enhancer forming an antibody-radio frequency enhancing moiety-virion complex (ARFVC); removing the ARFVC from the body fluid using a radiofrequency source; and returning the body fluid to the patient. Other aspects are described and claimed.

The invention concerns biocompatible polymer systems comprising at least one polymer with a plurality of pores, said polymer comprising a sulfonic acid salt functionality designed to adsorb a broad range of protein based toxins from less than 0.5 kDa to 1,000 kDa and positively charged ions including but not limited to potassium.

A method of performing dialysis includes: recirculating a dialysis fluid from a patient or a dialyzer for at least two cycles, each cycle contacting the dialysis fluid first with a zirconium phosphate layer followed by at least one of a urease layer, a zirconium oxide layer, or a carbon layer; storing the recirculated dialysis fluid in a storage container; and transferring the dialysis fluid from the storage container to the patient or the dialyzer. In one example, the zirconium phosphate layer and the at least one of the urease layer, the zirconium oxide layer, or the carbon layer is provided by a sorbent cartridge.